TIMOPTIC IN OCUDOSE

LOE Approaching

timolol maleate

Bausch + Lomb

NDAOPHTHALMICSOLUTION/DROPS

Approved

Nov 1986

Lifecycle

LOE Approaching

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

TIMOPTIC IN OCUDOSE (timolol maleate) by Bausch + Lomb is components: dorzolamide hydrochloride and timolol maleate. Approved for ocular hypertension, open-angle glaucoma. First approved in 1986.

Drug data last refreshed 22h ago · AI intelligence enriched 2w ago

AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data

TIMOPTIC IN OCUDOSE is a fixed-dose combination ophthalmic solution containing timolol maleate (a non-selective beta-adrenergic receptor blocker) and dorzolamide hydrochloride (a carbonic anhydrase inhibitor) for treating ocular hypertension and open-angle glaucoma. Both components reduce intraocular pressure by decreasing aqueous humor secretion, with the combination providing additive IOP-lowering effects. The product is administered as eye drops twice daily.

LOE Approaching

Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team downsizing and transition toward generic management strategies.

Mechanism of Action

components: Dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma, by reducing aqueous humor secretion. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve…

Indications (2)

Ocular Hypertension

Worked on TIMOPTIC IN OCUDOSE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (9)

NCT04830397Phase 2Completed

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

Started Mar 2021

84 enrolled

Primary Open Angle GlaucomaOcular Hypertension

NCT04742283Phase 2Completed

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Started Dec 2020

323 enrolled

Primary Open Angle GlaucomaOcular Hypertension

NCT03691662Phase 3Completed

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Started Sep 2018

417 enrolled

Glaucoma and Ocular Hypertension

NCT03691649Phase 3Completed

Started Sep 2018

426 enrolled

Glaucoma and Ocular Hypertension

NCT03519386Phase 3Completed

Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%

Started Jul 2018

590 enrolled

Glaucoma, Open-AngleOcular Hypertension

Career Relevance

Working on TIMOPTIC IN OCUDOSE offers limited career growth opportunity given LOE approaching status and zero linked job openings; the role is primarily defensive, focused on market-share retention and generic transition management. Career progression is more likely on newer products like VYZULTA (same sponsor) or competitor growth-stage brands.

Brand ManagerProduct ManagerField Sales RepresentativeMedical Science LiaisonRegional Sales Director

CommercialSalesMedical AffairsMarket Access

Company

Bausch + Lomb

NJ - Bridgewater

See all Bausch + Lomb products →

External Resources

Official Product Website

Patient information & support programs

ClinicalTrials.gov

Active clinical trials for this drug

DailyMed

Full prescribing information